Evolving Therapeutic Strategies in Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumors (GISTs) account for 20% of sarcomatous tumors and 1−2% of primary gastrointestinal cancers. When localized and operable, GISTs have a favorable prognosis with a five-year overall survival of around 80%. In the metastatic setting, the prognosis is poor with limited the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2023.17.118 |